A crossover, add-on trial of talampanel in patients with refractory partial seizures

Ovid Technologies (Wolters Kluwer Health) - Tập 58 Số 11 - Trang 1680-1682 - 2002
Amy S. Chappell1,2,3,4,5, Josemir W. Sander1,2,3,4,5, M.J. Brodie1,2,3,4,5, D Chadwick1,2,3,4,5, A. Lledó1,2,3,4,5, Dingguo Zhang1,2,3,4,5, J.S. Bjerke1,2,3,4,5, G.M. Kiesler1,2,3,4,5, Santiago Arroyo1,2,3,4,5
1Department of Clinical and Experimental Epilepsy (Dr. Sander), Institute of Neurology, University College London, United Kingdom
2Epilepsy Unit (Dr. Arroyo), Hospital Clinic de Barcelona, Spain.
3Epilepsy Unit (Dr. Brodie), University Department of Medicine and Therapeutics
4From Eli Lilly and Company (Drs. Chappell, Lledo, Zhang, Bjerke, and Kiesler), Lilly Corporate Center, Indianapolis, IN; Department of Clinical and Experimental Epilepsy (Dr. Sander), Institute of Neurology, University College London, United Kingdom; Epilepsy Unit (Dr. Brodie), University Department of Medicine and Therapeutics; Walton Hospital (Dr. Chadwick), United Kingdom; and Epilepsy Unit (Dr. Arroyo), Hospital Clinic de Barcelona, Spain.
5Walton Hospital (Dr. Chadwick), United Kingdom

Tóm tắt

Từ khóa


Tài liệu tham khảo

10.1111/j.1527-3458.1996.tb00292.x

10.1016/S0028-3908(96)00156-6

10.1016/S0028-3908(96)00155-4

Kallman MJ, Tizzano JP, Modlin DL, et al. Behavioral characterization of a noncompetitive AMPA antagonist LY300164. Soc Neurosci Abstr . 1995; 21 (Pt 1): 350.

Jewell H, Lucas R, Schaefer H, Mant T. LY300164 initial experience in healthy subjects. Clin Pharmacol Ther . 1998; 63: 188.

10.1111/j.1528-1157.1989.tb05316.x

10.1111/j.2044-8341.1974.tb02285.x

10.1037/h0061266

10.2307/2528104

Thông tin
Thông tin xuất bản

Ovid Technologies (Wolters Kluwer Health)

Tập 58 Số 11

1680-1682

Thông tin tác giả